FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2303764791> ?p ?o ?g. }

• W2303764791 endingPage "5504" @default.
• W2303764791 startingPage "5504" @default.
• W2303764791 abstract "Abstract Abstract 5504 Backgroud Allogeneic transplantation (HSCT) is the only potentially curative therapy for myelofibrosis, even in the era of new drugs that only impact on selected manifestations of disease. The time to evolution of myelofibrosis in advanced phases is variable (months to several years). The choice to proceed to allogeneic transplantation is based on several clinical variables; conditioning regimen and time to transplantation may influence the outcome of HSCT. Here we present our experience in a group of patients with myelofibrosis transplanted in Our Center with a myeloablative regimen based on full dose of treosulfan. Methods We retrospectively evaluated 20 patients (15 male) with primary myelofibrosis (14) and post-ET (essential thrombocythemia) myelofibrosis (6) who underwent HSCT at our institute from July 2005 to February 2013. In this cohort we included 4 patients in blast phase, 3 of which received a brief course of chemotherapy prior to transplant; 4 patients who underwent a second allogeneic transplantation for disease relapse (2) or graft failure (1); 1 patient referred at our Institute in graft failure 3 months after first HSCT. Only 1 patient had splenectomy before HSCT. Results The median age at diagnosis was 59 years (range 41-76). JAK2 V617F mutation was positive in 7 and unknown in 3 patients. In post-ET MF patients, the median time to transformation in MF was 134 months (60-144). The median time from diagnosis to transplant was 14 months (4-101 months). The median age at transplant was 62 years. DIPSS score at transplant was low in 1, int-1 in 3, int-2 in 13 and high in 3 patients. We adopted myeloablative regimen based on treosulfan 42 gr/ms and fludarabine 150 mg/ms, plus TBI 4 Gy in 7 patients. GvHD prophylaxis was based on ATG, Rituximab and CSA/MTX (8 pts) or rapamycin (11 pts). The graft was PBSCs (19) and BM (1) from related HLA-identical donor (7 pts), matched unrelated donor (5 pts) and haploidentical donor (8 pts). The incidence of graft failure and poor graft function was 5% and 20% respectively. The median time to neutrophils engraftment was 20 days. The incidence of acute and chronic graft versus host disease was 50% and 40% respectively. Cumulative incidence of TRM (transplant related mortality) was 45 %; day 100 OS (overall survival) was 70% while 2 year OS was 40%. In multivariate analysis there was no statistically significant correlation between individual factors (including WBC, hemoglobin, platelets, ferritin, beta2-microglobulin, IgA, IgG, IgM, LDH, psuedocholinesterase levels, age, Sorror comorbidity score, donor match, bone marrow kariotype) and survival. However, we found that a linear composition of level of peripheral blasts (0%, ≥1%, ≥5%), bone marrow CD34+ cells (<5%, ≥5%, ≥20%), spleen size and number of red blood cells units transfused pre-HSCT is able to predict the outcome (p-value 0.03), even if each factor alone is not strongly correlated with survival. There was no statistical significant correlation between the outcome and DIPSS score, Bacicalupo score and Lille score. Conclusions A myeloablative regimen based on full dose treosulfan provide a 95% rate of primary allogeneic engraftment and 40% overall survival in myelofibrosis at advanced stage, with low extra-hematological toxicity in frail patients. Allogeneic transplantation after myeloablative low-toxicity regimens may be offered in myelofibrosis in early chronic phase of disease and for younger patients, two conditions usually linked with durable engraftment, low toxicities and low rate of relapse. Disclosures: No relevant conflicts of interest to declare." @default.
• W2303764791 created "2016-06-24" @default.
• W2303764791 creator A5004153853 @default.
• W2303764791 creator A5009840248 @default.
• W2303764791 creator A5012911614 @default.
• W2303764791 creator A5026667594 @default.
• W2303764791 creator A5030793344 @default.
• W2303764791 creator A5032192705 @default.
• W2303764791 creator A5045645624 @default.
• W2303764791 creator A5054335870 @default.
• W2303764791 creator A5059381857 @default.
• W2303764791 creator A5074043746 @default.
• W2303764791 creator A5076929140 @default.
• W2303764791 creator A5082083571 @default.
• W2303764791 creator A5086372056 @default.
• W2303764791 date "2013-11-15" @default.
• W2303764791 modified "2023-10-18" @default.
• W2303764791 title "Treosulfan Based Myeloablative Regimen Provides High Rate Of Allogeneic Engraftment and Low Toxicity In Patients With Advanced Myelofibrosis," @default.
• W2303764791 doi "https://doi.org/10.1182/blood.v122.21.5504.5504" @default.
• W2303764791 hasPublicationYear "2013" @default.
• W2303764791 type Work @default.
• W2303764791 sameAs 2303764791 @default.
• W2303764791 citedByCount "1" @default.
• W2303764791 countsByYear W23037647912022 @default.
• W2303764791 crossrefType "journal-article" @default.
• W2303764791 hasAuthorship W2303764791A5004153853 @default.
• W2303764791 hasAuthorship W2303764791A5009840248 @default.
• W2303764791 hasAuthorship W2303764791A5012911614 @default.
• W2303764791 hasAuthorship W2303764791A5026667594 @default.
• W2303764791 hasAuthorship W2303764791A5030793344 @default.
• W2303764791 hasAuthorship W2303764791A5032192705 @default.
• W2303764791 hasAuthorship W2303764791A5045645624 @default.
• W2303764791 hasAuthorship W2303764791A5054335870 @default.
• W2303764791 hasAuthorship W2303764791A5059381857 @default.
• W2303764791 hasAuthorship W2303764791A5074043746 @default.
• W2303764791 hasAuthorship W2303764791A5076929140 @default.
• W2303764791 hasAuthorship W2303764791A5082083571 @default.
• W2303764791 hasAuthorship W2303764791A5086372056 @default.
• W2303764791 hasConcept C126322002 @default.
• W2303764791 hasConcept C141071460 @default.
• W2303764791 hasConcept C2776694085 @default.
• W2303764791 hasConcept C2777408962 @default.
• W2303764791 hasConcept C2778837598 @default.
• W2303764791 hasConcept C2779178397 @default.
• W2303764791 hasConcept C2779709957 @default.
• W2303764791 hasConcept C2780007613 @default.
• W2303764791 hasConcept C2780076729 @default.
• W2303764791 hasConcept C2780611847 @default.
• W2303764791 hasConcept C2781057849 @default.
• W2303764791 hasConcept C2781413609 @default.
• W2303764791 hasConcept C2911091166 @default.
• W2303764791 hasConcept C71924100 @default.
• W2303764791 hasConceptScore W2303764791C126322002 @default.
• W2303764791 hasConceptScore W2303764791C141071460 @default.
• W2303764791 hasConceptScore W2303764791C2776694085 @default.
• W2303764791 hasConceptScore W2303764791C2777408962 @default.
• W2303764791 hasConceptScore W2303764791C2778837598 @default.
• W2303764791 hasConceptScore W2303764791C2779178397 @default.
• W2303764791 hasConceptScore W2303764791C2779709957 @default.
• W2303764791 hasConceptScore W2303764791C2780007613 @default.
• W2303764791 hasConceptScore W2303764791C2780076729 @default.
• W2303764791 hasConceptScore W2303764791C2780611847 @default.
• W2303764791 hasConceptScore W2303764791C2781057849 @default.
• W2303764791 hasConceptScore W2303764791C2781413609 @default.
• W2303764791 hasConceptScore W2303764791C2911091166 @default.
• W2303764791 hasConceptScore W2303764791C71924100 @default.
• W2303764791 hasIssue "21" @default.
• W2303764791 hasLocation W23037647911 @default.
• W2303764791 hasOpenAccess W2303764791 @default.
• W2303764791 hasPrimaryLocation W23037647911 @default.
• W2303764791 hasRelatedWork W1495196824 @default.
• W2303764791 hasRelatedWork W1537281129 @default.
• W2303764791 hasRelatedWork W2023241971 @default.
• W2303764791 hasRelatedWork W2087934326 @default.
• W2303764791 hasRelatedWork W2150058579 @default.
• W2303764791 hasRelatedWork W2503728834 @default.
• W2303764791 hasRelatedWork W2611711560 @default.
• W2303764791 hasRelatedWork W2980614848 @default.
• W2303764791 hasRelatedWork W4283271588 @default.
• W2303764791 hasRelatedWork W4284988614 @default.
• W2303764791 hasVolume "122" @default.
• W2303764791 isParatext "false" @default.
• W2303764791 isRetracted "false" @default.
• W2303764791 magId "2303764791" @default.
• W2303764791 workType "article" @default.